Phase I/II Radiation Dose-Escalation Trial of Intensity Modulated Radiotherapy (IMRT) with Concurrent Fixed Dose-Rate Gemcitabine (FDR-G) for Unresectable Pancreatic Cancer

被引：4
|
作者：
Ben-Josef, E. [1 ]
Schipper, M. [1 ]
Francis, I. [1 ]
Khan, G. [1 ]
Hadley, S. [1 ]
Lawrence, T. [1 ]
Simeone, D. [1 ]
Abrams, R. [2 ]
Sonnenday, C. [1 ]
Zalupski, M. [1 ]
机构：
[1] Univ Michigan, Med Ctr, Ann Arbor, MI USA
[2] Rush Univ, Med Ctr, Chicago, IL 60612 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 81卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2011.06.263
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S127 / S128
页数：2
相关论文
共 50 条
  • [1] Phase I radiation dose-escalation trial of intensity-modulated radiotherapy (IMRT) with concurrent fixed dose-rate gemcitabine (FDR-G) for unresectable pancreatic cancer
    Ben-Josef, E.
    Griffith, K.
    Francis, I. R.
    Khan, G.
    Lawrence, T. S.
    Abrams, R.
    Leslie, W.
    Zalupski, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [2] A Phase I/II Trial of Intensity Modulated Radiation (IMRT) Dose Escalation With Concurrent Fixed-dose Rate Gemcitabine (FDR-G) in Patients With Unresectable Pancreatic Cancer
    Ben-Josef, Edgar
    Schipper, Mathew
    Francis, Isaac R.
    Hadley, Scott
    Ten-Haken, Randall
    Lawrence, Theodore
    Normolle, Daniel
    Simeone, Diane M.
    Sonnenday, Christopher
    Abrams, Ross
    Leslie, William
    Khan, Gazala
    Zalupski, Mark M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (05): : 1166 - 1171
  • [3] Prognostic Value of CA 19-9 in a Phase I/II Trial of Dose Escalated Intensity Modulated Radiation Therapy (IMRT) With Concurrent Full-dose Gemcitabine (G) in Unresectable Pancreatic Cancer
    Vainshtein, J. M.
    Schipper, M.
    Zalupski, M.
    Lawrence, T. S.
    Abrams, R.
    Francis, I. R.
    Leslie, W.
    Ben-Josef, E.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S146 - S147
  • [4] Phase I trial of gefitinib with concurrent radiotherapy and fixed dose-rate gemcitabine infusion, in locally advanced pancreatic cancer.
    Maurel, J.
    Martin-Richard, M.
    Conill, C.
    Sanchez, M.
    Petriz, L.
    Ginés, A.
    Gallego, R.
    Cajal, R.
    Navarro, S.
    Fernandez-Cruz, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 204S - 204S
  • [5] Phase I Trial of Gemcitabine Dose Escalation with Concurrent Radiotherapy for Patients with Locally Advanced Pancreatic Cancer
    Nishida, Tsutomu
    Tsutsui, Shusaku
    Yamamoto, Katsumi
    Konishi, Koji
    Hayashi, Yoshito
    Iijima, Hideki
    Tsujii, Masahiko
    Takeda, Yutaka
    Kitagawa, Toru
    Yoshioka, Yasuo
    Inoue, Takehiro
    Hayashi, Norio
    PANCREATOLOGY, 2010, 10 (01) : 60 - 65
  • [6] Adjuvant therapy in pancreatic cancer: Phase I trial of radiation dose escalation with concurrent full-dose gemcitabine
    Allen, AM
    Zalupski, MM
    Robertson, JM
    Eckhauser, FE
    Simone, D
    Brown, D
    Hejna, G
    Normolle, D
    Lawrence, TS
    McGinn, CJ
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (05): : 1461 - 1467
  • [7] Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer
    McGinn, CJ
    Zalupski, MM
    Shureiqi, I
    Robertson, JM
    Eckhauser, FE
    Smith, DC
    Brown, D
    Hejna, G
    Strawderman, M
    Normolle, D
    Lawrence, TS
    JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (22) : 4202 - 4208
  • [8] Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
    Santini, D.
    Vincenzi, B.
    Masi, G.
    Catalano, V
    Virzi, V.
    Vasile, E.
    Fontana, A.
    Intagliata, S.
    Catalano, G.
    Falcone, A.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2008, 19 : 59 - 60
  • [9] PHASE II CAPECITABINE AND GEMCITABINE FIXED DOSE RATE (FDR) IN PATIENTS WITH ADVANCED PANCREATIC CANCER
    Santini, D.
    Vincenzi, B.
    Masi, G.
    Catalano, V
    Virzi, V.
    Vasile, E.
    Fontana, A.
    Intagliata, S.
    Catalano, G.
    Falcone, A.
    Tonini, G.
    ANNALS OF ONCOLOGY, 2009, 20 : 104 - 104
  • [10] Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
    Tonini, G.
    Vincenzi, B.
    Vasile, E.
    Catalano, V.
    Virzi, V.
    Fontana, A.
    Intagliata, S.
    Catalano, G.
    Falcone, A.
    Santini, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345